Skip to main content
Laekna, Inc. logo

Laekna, Inc. — Investor Relations & Filings

Ticker · 2105 ISIN · KYG5340S1093 LEI · 984500530D69C0FD1D94 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 136 across all filing types
Latest filing 2024-08-26 Interim / Quarterly Rep…
Country HK Hong Kong
Listing HKEX 2105

About Laekna, Inc.

http://www.laekna.com

Laekna, Inc. is a science-driven, clinical-stage biotechnology company founded in 2016. The company specializes in the discovery, development, and commercialization of innovative therapies, particularly focusing on immunology treatments. Laekna's core mission is to bring novel therapeutics to patients suffering from cancer (oncology), metabolic diseases, and liver fibrosis, addressing significant unmet medical needs across these therapeutic areas.

Recent filings

Filing Released Lang Actions
Interim Report 2024
Interim / Quarterly Report Classification · 95% confidence The document contains a detailed table of contents including sections such as 'Management Discussion and Analysis', 'Corporate Governance and Other Information', 'Independent Review Report', and various consolidated financial statements. The presence of 'Notes to the Unaudited Interim Financial Report' and the term 'Interim Report 2024' clearly indicates that this is a financial report covering a period shorter than a full fiscal year. The document length is substantial (15,000 characters), and it contains actual financial data and analysis rather than just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-26 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024' and contains detailed unaudited condensed consolidated interim financial results, including profit or loss statements, financial position, cash flow statements, and notes to the interim financial information. It covers a six-month period ending June 30, 2024, which is a period shorter than a full fiscal year. The document includes substantive financial data and analysis, not merely an announcement or a link to a report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-16 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is an announcement from Laekna, Inc. regarding the scheduling of a board meeting to consider and approve the interim results for the six months ended 30 June 2024. It does not contain the actual interim financial results or substantive financial data, but rather informs about the upcoming board meeting and the intention to publish the interim results. The document is short (1273 characters) and serves as a notice rather than a report. According to the 'MENU VS MEAL' rule, such announcements about report publication or board meetings are classified as Regulatory Filings (RNS) rather than the Interim Report (IR) itself.
2024-08-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
Regulatory Filings Classification · 95% confidence The document is a detailed monthly return report submitted to the Hong Kong Exchanges and Clearing Limited regarding movements in securities for the month ended 31 July 2024. It includes detailed tables on movements in authorized share capital, issued shares, share options, and confirmations related to compliance with listing rules. The document is regulatory in nature, reporting share capital and share issuance activities, but it is not an announcement of a financing event, nor a full financial report, nor a voting result. It is a regulatory filing required by the exchange to disclose share capital movements and confirmations. The document is about share capital movements and confirmations but does not announce new share issues or capital changes in the sense of a capital change announcement (SHA), nor is it a share repurchase (POS). It is not a proxy, AGM material, or earnings release. Given the nature and format, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document related to share capital movements under exchange rules.
2024-08-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 June 2024. It details movements in authorized share capital, issued shares, share options, and other share-related schemes. It includes confirmations pursuant to specific listing rules of the Hong Kong Stock Exchange. The document is a regulatory submission reporting share capital and share movement details for a specific month, consistent with regulatory compliance filings rather than a financial report or announcement of results. It does not contain financial statements, earnings data, or management discussion. It is a regulatory filing reporting share capital movements and confirmations under listing rules.
2024-07-05 English
VOLUNTARY ANNOUNCEMENT FIRST SUBJECT DOSED IN PHASE I CLINICAL TRIAL OF LAE102 FOR THE TREATMENT OF OBESITY
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Laekna, Inc. regarding the dosing of the first subject in a Phase I clinical trial for a drug candidate LAE102. It provides a business update about the clinical trial progress and drug details but does not contain financial statements, regulatory certifications, or detailed financial data. The document is relatively short (2568 characters) and serves as a business update rather than a formal financial or regulatory report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings related to financial disclosures. It is also not a report publication announcement since it does not mention the release or availability of a report. The content is a business update announcement about clinical trial progress, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-06-26 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.